
NeoGenomics (NEO) Stock Forecast & Price Target
NeoGenomics (NEO) Analyst Ratings
Bulls say
NeoGenomics is a comprehensive provider of cancer diagnostic testing with a wide range of services, experienced team of professionals, and a strong network of labs. Despite margin and launch challenges, the company has consistently delivered strong revenue growth with a positive outlook for the future, driven by expanding capabilities and partnerships with pharma companies. With a strong leadership team, potential upside drivers and a dominant position in the market, NeoGenomics has the potential to continue its growth trajectory and solidify its position as a leading player in the oncology space. However, risks such as potential setbacks in reimbursement or patent litigation, negative changes in reimbursement, and potential competition from more focused companies should be monitored closely.
Bears say
NeoGenomics is facing major risks due to reduction in research and development budgets, reduced purchasing from healthcare and hospital customers, increased regulatory hurdles, and reliance on emerging markets. These risks have the potential to hinder revenue and profitability growth. Additionally, the company's current guidance for 4Q25 may not reflect sustainable growth, leading to potential disappointment when full results are announced, further contributing to a negative outlook.
This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.
NeoGenomics (NEO) Analyst Forecast & Price Prediction
Start investing in NeoGenomics (NEO)
Order type
Buy in
Order amount
Est. shares
0 shares